Compare · DFTX vs TLRY
DFTX vs TLRY
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Tilray Brands Inc. (TLRY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and TLRY operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $2.02B, about 2.8x TLRY ($715.4M).
- Over the past year, DFTX is up 227.1% and TLRY is up 27.1% - DFTX leads by 200.0 points.
- TLRY has been more active in the news (13 items in the past 4 weeks vs 9 for DFTX).
- TLRY has more recent analyst coverage (14 ratings vs 4 for DFTX).
- Company
- Definium Therapeutics Inc.
- Tilray Brands Inc.
- Price
- $20.87+1.85%
- $6.15+0.00%
- Market cap
- $2.02B
- $715.4M
- 1M return
- +10.48%
- -4.87%
- 1Y return
- +227.12%
- +27.14%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 9
- 13
- Recent ratings
- 4
- 14
Tilray Brands Inc.
Tilray, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. The company operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development. It provides medical and adult-use cannabis products; pharmaceutical and wellness products; beverage alcohol products; and hemp-based food and other wellness products. The company offers its products to retailers, wholesalers, patients, physicians, pharmacies, clinics, hospitals, governments, and researchers. It has operations in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company was formerly known as Aphria Inc. Tilray, Inc. was incorporated in 2018 and is based in New York, New York.
Latest DFTX
- SEC Form DEFA14A filed by Definium Therapeutics Inc.
- SEC Form DEF 14A filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
- Stifel initiated coverage on Definium Therapeutics with a new price target
- Piper Sandler initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
- New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States
Latest TLRY
- Manitoba Harvest Launches Superfood Smoothie Boosters, Exclusively at Sprouts Farmers Market Nationwide
- Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling
- BrewDog USA Doubles Down on Headliners and Ignites Next Wave of Innovation for Spring and Summer
- SEC Form 4 filed by Hopkinson David G.
- Tilray Brands Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B7 filed by Tilray Brands Inc.
- Tilray Brands Marks 4/20, Reaffirming Its Leadership in Cannabis and Commitment to Advancing Medical Care
- SEC Form 424B5 filed by Tilray Brands Inc.
- Tilray Brands Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership